Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer

  • Bae, Sun Hyun (Department of Radiation Oncology, Soonchunhyang University College of Medicine) ;
  • Moon, Seong Kwon (Department of Radiation Oncology, Soonchunhyang University College of Medicine) ;
  • Kim, Yong Ho (Department of Radiation Oncology, Catholic Kwandong University International St. Mary's Hospital) ;
  • Cho, Kwang Hwan (Department of Radiation Oncology, Soonchunhyang University College of Medicine) ;
  • Shin, Eung Jin (Department of General Surgery, Soonchunhyang University College of Medicine) ;
  • Lee, Moon Sung (Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Ryu, Chang Beom (Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Ko, Bong Min (Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Yun, Jina (Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine)
  • Received : 2015.11.02
  • Accepted : 2015.12.10
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the treatment outcome and the toxicity of helical tomotherapy (HT) in patients with metastatic colorectal cancer (mCRC). Materials and Methods: We retrospectively reviewed 18 patients with 31 lesions from mCRC treated with HT between 2009 and 2013. The liver (9 lesions) and lymph nodes (9 lesions) were the most frequent sites. The planning target volume (PTV) ranged from 12 to 1,110 mL (median, 114 mL). The total doses ranged from 30 to 70 Gy in 10-30 fractions. When the ${\alpha}/{\beta}$ value for the tumor was assumed to be 10 Gy for the biologically equivalent dose (BED), the total doses ranged from 39 to $119Gy_{10}$ (median, $55Gy_{10}$). Nineteen lesions were treated with concurrent chemotherapy (CCRT). Results: With a median follow-up time of 16 months, the median overall survival for 18 patients was 33 months. Eight lesions (26%) achieved complete response. The 1- and 3-year local progression free survival (LPFS) rates for 31 lesions were 45% and 34%, respectively. On univariate analysis, significant parameters influencing LPFS rates were chemotherapy response before HT, aim of HT, CCRT, PTV, BED, and adjuvant chemotherapy. On multivariate analysis, $PTV{\leq}113mL$ and $BED>48Gy_{10}$ were associated with a statistically significant improvement in LFPS. During HT, four patients experienced grade 3 hematologic toxicities, each of whom had also received CCRT. Conclusion: The current study demonstrates the efficacy and tolerability of HT for mCRC. To define optimal RT dose according to tumor size of mCRC, further study should be needed.

Keywords

References

  1. Fairchild A, Barnes E, Ghosh S, et al. International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys 2009;75:1501-10. https://doi.org/10.1016/j.ijrobp.2008.12.084
  2. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012;24:112-24. https://doi.org/10.1016/j.clon.2011.11.004
  3. Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol 2014;32:2913-9. https://doi.org/10.1200/JCO.2014.55.1143
  4. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10. https://doi.org/10.1200/JCO.1995.13.1.8
  5. Jones JA, Simone CB 2nd. Palliative radiotherapy for advanced malignancies in a changing oncologic landscape: guiding principles and practice implementation. Ann Palliat Med 2014; 3:192-202.
  6. Van Cutsem E, Nordlinger B, Cervantes A; ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21 Suppl 5:v93-7. https://doi.org/10.1093/annonc/mdq222
  7. Cheng YD, Yang H, Chen GQ, Zhang ZC. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther 2013;7:1315-22.
  8. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-34. https://doi.org/10.1200/JCO.2008.16.3212
  9. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014;371:1609-18. https://doi.org/10.1056/NEJMoa1403108
  10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  11. Engels B, Gevaert T, Everaert H, et al. Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer. Radiat Oncol 2012;7:34. https://doi.org/10.1186/1748-717X-7-34
  12. Nielsen LB, Wille-Jorgensen P. National and international guidelines for rectal cancer. Colorectal Dis 2014;16:854-65. https://doi.org/10.1111/codi.12678
  13. Bak K, Dobrow MJ, Hodgson D, Whitton A. Factors affecting the implementation of complex and evolving technologies: multiple case study of intensity-modulated radiation therapy (IMRT) in Ontario, Canada. BMC Health Serv Res 2011;11:178. https://doi.org/10.1186/1472-6963-11-178
  14. Guadagnolo BA, Huo J, Liao KP, Buchholz TA, Das P. Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States. Cancer 2013;119:1089-97. https://doi.org/10.1002/cncr.27835
  15. Piotrowski T, Skorska M, Jodda A, et al. Tomotherapy: a different way of dose delivery in radiotherapy. Contemp Oncol (Pozn) 2012;16:16-25.
  16. Samant R, Gerig L, Montgomery L, et al. The emerging role of IG-IMRT for palliative radiotherapy: a single-institution experience. Curr Oncol 2009;16:40-5.
  17. Lee IJ, Seong J, Lee CG, et al. Early clinical experience and outcome of helical tomotherapy for multiple metastatic lesions. Int J Radiat Oncol Biol Phys 2009;73:1517-24. https://doi.org/10.1016/j.ijrobp.2008.07.035
  18. Choi Y, Kim JW, Lee IJ, Han HJ, Baek J, Seong J. Helical tomotherapy for spine oligometastases from gastrointestinal malignancies. Radiat Oncol J 2011;29:219-27. https://doi.org/10.3857/roj.2011.29.4.219
  19. Kim JY, Kay CS, Kim YS, et al. Helical tomotherapy for simultaneous multitarget radiotherapy for pulmonary metastasis. Int J Radiat Oncol Biol Phys 2009;75:703-10. https://doi.org/10.1016/j.ijrobp.2008.11.065
  20. Engels B, Everaert H, Gevaert T, et al. Phase II study of helical tomotherapy for oligometastatic colorectal cancer. Ann Oncol 2011;22:362-8. https://doi.org/10.1093/annonc/mdq385
  21. Lee JH, Lee JH, Jang HS, et al. Hypofractionated radiotherapy with tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions. Clin Exp Metastasis 2013;30:643-50. https://doi.org/10.1007/s10585-013-9568-7
  22. Bae SH, Kim MS, Cho CK, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 2012;106:138-43. https://doi.org/10.1002/jso.23058
  23. Strom HH, Bremnes RM, Sundstrom SH, Helbekkmo N, Aasebo U. Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial. J Thorac Oncol 2014;9:825-33. https://doi.org/10.1097/JTO.0000000000000184
  24. Comito T, Cozzi L, Clerici E, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 2014;14:619. https://doi.org/10.1186/1471-2407-14-619
  25. Bae SH, Park W, Choi DH, et al. Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer. Radiat Oncol 2011;6:52. https://doi.org/10.1186/1748-717X-6-52
  26. Cameron MG, Kersten C, Vistad I, Fossa S, Guren MG. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer: a systematic review. Acta Oncol 2014;53:164-73. https://doi.org/10.3109/0284186X.2013.837582
  27. Van den Begin R, Engels B, Gevaert T, et al. Impact of inadequate respiratory motion management in SBRT for oligometastatic colorectal cancer. Radiother Oncol 2014;113:235-9. https://doi.org/10.1016/j.radonc.2014.11.005
  28. Ahmed KA, Fulp WJ, Berglund AE, et al. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys 2015;92:837-42. https://doi.org/10.1016/j.ijrobp.2015.01.036
  29. Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol 1961;5:255-8. https://doi.org/10.1088/0031-9155/5/3/302
  30. Mohiuddin M, Marks G, Marks J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 2002;95:1144-50. https://doi.org/10.1002/cncr.10799
  31. Guren MG, Undseth C, Rekstad BL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol 2014;113:151-7. https://doi.org/10.1016/j.radonc.2014.11.021